LENVA 4MG TAB 10'S

About

Lenvatinib is a multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4, platelet-derived growth factor receptor (PDGFR) alpha, RET, and KIT. By inhibiting these receptor tyrosine kinases, lenvatinib impedes tumor angiogenesis, tumor growth, and other pro-oncogenic signaling pathways. It is an oral medication used in the treatment of various advanced cancers, including differentiated thyroid cancer (DTC) refractory to radioactive iodine, advanced renal cell carcinoma (RCC) in combination with everolimus, and unresectable hepatocellular carcinoma (HCC). Its broad spectrum of kinase inhibition contributes to its efficacy in these challenging malignancies by disrupting multiple pathways critical for tumor progression and metastasis.

Uses

• Radioactive iodine-refractory differentiated thyroid cancer
• Advanced renal cell carcinoma (in combination)
• Unresectable hepatocellular carcinoma
• Endometrial carcinoma (in combination)

Directions For Use

Take orally once daily, with or without food, as directed by a physician. Do not crush or chew the capsules.

Benefits

• Significant improvement in progression-free survival.
• Effective in difficult-to-treat advanced cancers.
• Oral administration offers convenience.
• Targets multiple pathways crucial for tumor growth.
• Approved for several distinct cancer types.
• Can be used as monotherapy or in combination.

Side Effects

• Hypertension
• Fatigue
• Diarrhea
• Decreased appetite
• Weight loss
• Nausea
• Proteinuria
• Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)
• Hypothyroidism
• Headache
• Vomiting
• Abdominal pain

Safety Measures

• Alcohol - No specific interaction known, but excessive alcohol may worsen liver function or gastrointestinal side effects.
• Pregnancy - Contraindicated in pregnancy due to potential for embryofetal toxicity. Use effective contraception during and for at least one month after treatment.
• Breastfeeding - Not recommended during breastfeeding as lenvatinib may be excreted in breast milk and harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments are necessary for moderate to severe impairment.
• Kidney - Use with caution in patients with severe renal impairment; dose adjustments may be required.
• Lung - Rare but serious pulmonary embolism or interstitial lung disease can occur; monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.